187 related articles for article (PubMed ID: 9649137)
1. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.
Brinkschmidt C; Poremba C; Christiansen H; Simon R; Schäfer KL; Terpe HJ; Lampert F; Boecker W; Dockhorn-Dworniczak B
Br J Cancer; 1998 Jun; 77(12):2223-9. PubMed ID: 9649137
[TBL] [Abstract][Full Text] [Related]
2. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
[TBL] [Abstract][Full Text] [Related]
4. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization.
Vandesompele J; Van Roy N; Van Gele M; Laureys G; Ambros P; Heimann P; Devalck C; Schuuring E; Brock P; Otten J; Gyselinck J; De Paepe A; Speleman F
Genes Chromosomes Cancer; 1998 Oct; 23(2):141-52. PubMed ID: 9739017
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic analysis of infantile neuroblastomas by comparative genomic hybridization.
Iehara T; Hamazaki M; Sawada T
Cancer Lett; 2002 Apr; 178(1):83-9. PubMed ID: 11849745
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Boecker W; Lampert F; Stoerkel S
J Pathol; 1997 Apr; 181(4):394-400. PubMed ID: 9196436
[TBL] [Abstract][Full Text] [Related]
7. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
8. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?
Vandesompele J; Speleman F; Van Roy N; Laureys G; Brinskchmidt C; Christiansen H; Lampert F; Lastowska M; Bown N; Pearson A; Nicholson JC; Ross F; Combaret V; Delattre O; Feuerstein BG; Plantaz D
Med Pediatr Oncol; 2001 Jan; 36(1):5-10. PubMed ID: 11464905
[TBL] [Abstract][Full Text] [Related]
9. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
[TBL] [Abstract][Full Text] [Related]
10. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Van Roy N; Jauch A; Van Gele M; Laureys G; Versteeg R; De Paepe A; Cremer T; Speleman F
Cancer Genet Cytogenet; 1997 Sep; 97(2):135-42. PubMed ID: 9283597
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
[TBL] [Abstract][Full Text] [Related]
12. Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
Iolascon A; Lo Cunsolo C; Giordani L; Cusano R; Mazzocco K; Boumgartner M; Ghisellini P; Faienza MF; Boni L; De Bernardi B; Conte M; Romeo G; Tonini GP
Cancer Lett; 1998 Aug; 130(1-2):83-92. PubMed ID: 9751260
[TBL] [Abstract][Full Text] [Related]
13. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
14. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
Abel F; Ejeskär K; Kogner P; Martinsson T
Br J Cancer; 1999 Dec; 81(8):1402-9. PubMed ID: 10604740
[TBL] [Abstract][Full Text] [Related]
15. Telomerase activity as a prognostic factor in neuroblastomas.
Streutker CJ; Thorner P; Fabricius N; Weitzman S; Zielenska M
Pediatr Dev Pathol; 2001; 4(1):62-7. PubMed ID: 11200492
[TBL] [Abstract][Full Text] [Related]
16. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment.
Hirai M; Yoshida S; Kashiwagi H; Kawamura T; Ishikawa T; Kaneko M; Ohkawa H; Nakagawara A; Miwa M; Uchida K
Genes Chromosomes Cancer; 1999 Jul; 25(3):261-9. PubMed ID: 10379872
[TBL] [Abstract][Full Text] [Related]
17. Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis.
Krona C; Carén H; Sjöberg RM; Sandstedt B; Laureys G; Kogner P; Martinsson T
Int J Oncol; 2008 Mar; 32(3):575-83. PubMed ID: 18292934
[TBL] [Abstract][Full Text] [Related]
18. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis.
Poremba C; Willenbring H; Hero B; Christiansen H; Schäfer KL; Brinkschmidt C; Jürgens H; Böcker W; Dockhorn-Dworniczak B
Ann Oncol; 1999 Jun; 10(6):715-21. PubMed ID: 10442195
[TBL] [Abstract][Full Text] [Related]
20. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
